Specialized news

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1387
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => ivf08616.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-12-12
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-04 08:33:25
            [updated_time] => 2025-12-04 14:44:05
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => EUROFINS-GENTIS-conducts-technical-collaboration-at-Dong-Do-hospital-updates-on-ASEM-testing-in-assisted-reproduction
            [title] => EUROFINS GENTIS conducts technical collaboration at Dong Do hospital: updates on ASEM testing in assisted reproduction
            [description] => On November 28, the expert delegation from EUROFINS GENTIS, including Dr. Nguyen Quang Vinh (Director of the Genetic Counseling Center) and Dr. Pham Dinh Minh (Director of R&D), held a technical working session at Dong Do Hospital with the participation of the hospital’s reproductive medicine (IVF) team. This collaborative activity between EUROFINS GENTIS and Dong Do Hospital aimed to update the latest advances in genetic testing, thereby improving treatment outcomes for families struggling with infertility. The session not only facilitated academic exchange but also opened up new directions for long-term cooperation in the future.
            [content] => 
The meeting was attended by Dr. Tang Duc Cuong (Specialist Level II) – Director of Dong Do IVF Center, MSc. Dr. Ngo Thi Diem – Head of the Obstetrics Department, along with physicians, nurses, and laboratory technicians from the hospital.
During the discussion, Dr. Nguyen Quang Vinh presented an overview of the cell-free DNA PGT (ASEM test), a non-invasive embryo culture medium-based genetic test currently attracting attention in the field of IVF. He explained that this technique analyzes cell-free DNA (cfDNA) released from embryonic cells through apoptosis or necrosis, originating from both the inner cell mass (ICM) and the trophectoderm. However, to ensure accuracy, it is crucial to completely eliminate maternal granulosa or cumulus cells, as contamination with exogenous DNA can significantly affect the results.
Dr. Vinh also addressed several studies comparing the concordance between cfDNA in the culture medium and traditional biopsy samples such as TE, ICM, or cord blood, providing a comprehensive view of the test’s clinical potential. He emphasized that laboratory procedures in the IVF unit play a decisive role in sample quality—from thoroughly removing surrounding cells after fertilization, changing culture medium on Day 3, washing embryos carefully on Day 4, to culturing embryos in a 20 µl drop from the afternoon of Day 4 to Day 5 for at least 22 hours to obtain sufficient DNA. When the embryo reaches Day 5/Day 6, the technician collapses the embryo and collects the entire medium into a PCR tube with a preservation buffer, ensuring tip changes between samples and storing at -20°C to -80°C before analysis.
The ASEM test can detect aneuploidies of 22 autosomes, large structural abnormalities greater than 40Mb, and can report mosaicism at levels of 50% or higher. Results are available within approximately 7 days. Based on analytical data, experts provided clinical suggestions such as considering the transfer of 46XX embryos, with 46XY embryos being more strongly recommended, while embryos carrying abnormalities such as -1q or -15 deletions are generally not advised for transfer. Dr. Vinh concluded by stressing that ASEM technology only delivers real value when embryo culture, washing, and medium collection processes in the IVF laboratory are meticulously executed, as precision in every step determines the reliability and clinical relevance of the test results.
The session provided in-depth knowledge and important updates, contributing to Dong Do Hospital’s application of advanced genetic technologies to improve the effectiveness of assisted reproductive treatments.

Beyond theoretical presentation, Dr. Nguyen Quang Vinh also addressed clinicians’ questions regarding real clinical cases. These detailed analyses helped the Dong Do medical team better understand the coordination process between the IVF laboratory, IVF center, and testing unit to optimize patient outcomes.
Continuing the session, Dr. Vinh emphasized EUROFINS GENTIS’s development direction in implementing new technologies, expanding collaboration with IVF centers, and enhancing testing quality according to international standards. Dong Do Hospital highly appreciated the expert team’s updated insights and reaffirmed its readiness to collaborate in improving assisted reproductive care.
Concluding the exchange, Dr. Tang Đuc Cuong expressed his gratitude to the EUROFINS GENTIS delegation. He highlighted that the updated knowledge on ASEM testing not only helps clinicians better understand the potential of modern genetic techniques but also opens new approaches for optimizing embryo selection in difficult IVF cases. He affirmed that Dong Do Hospital is committed to closely cooperating with EUROFINS GENTIS to standardize procedures, enhance sample quality, and progress toward adopting ASEM as an important clinical support tool in the near future. According to Dr. Cương, this partnership will bring practical benefits to patients, especially infertile couples hoping for a chance to become parents.
The session concluded in an open and collaborative atmosphere. The event reaffirmed EUROFINS GENTIS’s commitment to providing precise, modern, and effective testing solutions, contributing to increasing the chances of parenthood for thousands of Vietnamese families.



            [content_more] => 
            [meta_title] => EUROFINS GENTIS conducts technical collaboration at Dong Do hospital: updates on ASEM testing in ass
            [meta_description] => On November 28, the expert delegation from EUROFINS GENTIS, including Dr. Nguyen Quang Vinh (Director of the Genetic Counseling Center) and Dr. Pham Dinh Minh (Director of R&D), held a technical working session at Dong Do Hospital with the participation o
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1387
            [category_id] => 15
        )

    [1] => stdClass Object
        (
            [id] => 1383
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => phat-hien-bat-thuong-gioi-tinh-tu-xet-nghiem-huyet-thong-4.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-11-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-11-25 09:02:49
            [updated_time] => 2025-11-28 08:46:30
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Detecting-sex-abnormalities-through-paternity-testing
            [title] => Detecting sex abnormalities through paternity testing
            [description] => In medicine, research on sex abnormalities in both males and females has produced many scientific publications based on different research and testing methods, not only after birth but even during pregnancy. However, in this article, we would like to share several cases of sex abnormalities that were detected during paternity testing.
            [content] => 
Case 1
The abnormality was discovered when a foreign man came to Eurofins Gentis to undergo an administrative father–child DNA test for birth registration and citizenship procedures. Based on the documents provided by the customer, the father was 36 years old, the child was a 5-month-old male, and the mother was a 20-year-old Vietnamese woman.
The testing was conducted according to standard procedures, and the results confirmed that the tested man and the child had a biological father–son relationship. The unusual point lay in the child’s sex. When analyzed using the 24-marker PowerPlex Fusion Kit, including Amelogenin and DYS391 for sex differentiation, the child’s genotype showed only XX at Amelogenin and no allele at DYS391, indicating a female genotype (see Peak image).

To establish a basis for concluding a sex abnormality, the company coordinated with the family to carry out a clinical examination, which confirmed that the child’s phenotype was male with clearly developed external genitalia.
Additionally, another test was performed to ensure accuracy: an analysis of the Y chromosome using the PowerPlex Y23 Kit. The results showed no Y-haplotype alleles at all (see Peak image).

Based on these findings, the company’s scientific council concluded that the child had 46, XX male syndrome (also known as XX Male Syndrome).
The cause of this phenomenon is unequal crossing-over between the Y chromosome and the X chromosome during the father’s meiosis. As a result, the X chromosome carries the SRY gene (the sex-determining gene). This occurs at the terminal region of the short arms of the X and Y chromosomes, where the SRY gene is normally located on the Y chromosome. When an X chromosome containing SRY combines with a normal maternal X chromosome at fertilization, it produces a 46, XX male genotype.
46, XX male syndrome occurs in approximately 1 in 20,000 newborn males, and individuals with this syndrome are infertile.
Case 2
A 42-year-old man visited the company with his 4-year-old son to request an administrative DNA test for father–son relationship verification. When asked why he wanted the test, he said he had a feeling the boy was not his because the child did not resemble him or his paternal relatives. His suspicion was emotional rather than factual—for accuracy, only DNA testing could provide an answer. Every customer has their own reasons for testing, often impossible to fully express.
Two days later, the results were completed. When he returned and learned that he and the boy were not biologically related, he fell silent for a moment, thanked the staff, and left.
About a week later, he returned again—this time with a prepared sample, stating it belonged to his 7-year-old daughter, and requested a comparison with his earlier sample. The results were astonishing: the daughter also had no biological relationship with him. Thus, both children he had tested were not his biological offspring.
Given the complicated circumstances, the scientific council analyzed the case carefully, especially because the Peak data at sex-related markers showed abnormalities. They decided to conduct an additional analysis using an X-test kit. The results revealed that the man had an XXY genotype, also known as Klinefelter syndrome (see Peak image).

The Peak chart clearly showed a male genotype (XY) at Amelogenin. However, most X-STR markers displayed two alleles (heterozygous), indicating two X chromosomes, while some X-STR markers showed a single peak (homozygous).
Klinefelter syndrome (XXY) occurs in males due to an extra X chromosome—typical males have XY. The syndrome arises randomly during gamete formation due to nondisjunction of sex chromosomes during meiosis. It occurs in approximately 1 in 500–1000 newborn males.

Males with XXY syndrome are typically infertile. Therefore, the fact that neither child was biologically related to him is understandable, and only the children’s mother would know who their biological father truly is.
Colonel Hà Quốc Khanh
            [content_more] => 
            [meta_title] => Detecting sex abnormalities through paternity testing
            [meta_description] => In medicine, research on sex abnormalities in both males and females has produced many scientific publications based on different research and testing methods, not only after birth but even during pregnancy.
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1383
            [category_id] => 15
        )

    [2] => stdClass Object
        (
            [id] => 1382
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => rabbit_media-5312.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-11-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-11-24 14:09:31
            [updated_time] => 2025-11-28 08:59:55
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-congratulates-the-20th-annual-HOSREM-scientific-conference-on-its-great-success
            [title] => Eurofins GENTIS congratulates the 20th annual HOSREM scientific conference on its great success
            [description] => On November 23, 2025, the 20th Annual HOSREM scientific conference took place at the Equatorial Hotel in Ho Chi Minh City, attracting a large number of doctors and experts in reproductive endocrinology, assisted reproduction, and embryology from across the country. Eurofins GENTIS was honored to accompany the event as a Sponsor, contributing to a well-organized, high-quality conference rich in scientific value.
            [content] => 
HOSREM – 20 years of building a prestigious scientific forum in reproductive endocrinology and infertility
The Ho Chi Minh City Society for Reproductive Endocrinology and Infertility (HOSREM) has spent 20 years building a mission-driven platform that provides a professional, up-to-date scientific environment for clinicians in obstetrics, gynecology, and assisted reproduction. Over two decades, the Annual HOSREM Scientific Conference has become an indispensable event for healthcare professionals, as it brings together advanced knowledge from leading experts, high-quality research reports, and the latest trends in the field both domestically and internationally. It is also a valuable space for networking, learning, and strengthening professional collaboration.

This year’s 20th conference continued to uphold its high standards, featuring a well-structured program with 5 scientific sessions, 20 specialized presentations, and 5 research-focused posters. The topics ranged from familiar clinical issues to cutting-edge techniques, meeting the diverse learning needs of the medical community.
Eurofins GENTIS: professional companion of the conference
As one of Vietnam’s leading genetic testing providers, Eurofins GENTIS is proud to once again accompany HOSREM—not only as a sponsor but also as a bridge bringing advanced genetic solutions closer to clinicians and experts in assisted reproduction and obstetrics. At this year’s conference, Eurofins GENTIS was honored to contribute professional data supporting the key scientific report delivered by Assoc. Prof. Dr. Trinh The Son (Director, Clinical Embryology Institute – Military Medical Academy), titled: “Genetic Causes and Assisted Reproduction in Azoospermia Patients.”

The report provided an in-depth analysis of the role of genetic testing in diagnosing azoospermia, covering gene mutations, Y-chromosome microdeletions, and other genetic abnormalities affecting spermatogenesis. Modern testing data from Eurofins GENTIS played a crucial role in case analysis and evidence presentation, enhancing the report’s scientific value and receiving positive feedback from attendees.
Eurofins GENTIS exhibition Booth – A highlight for many delegates
Alongside scientific activities, Eurofins GENTIS brought to the conference a modern, visually engaging booth showcasing a comprehensive range of genetic testing services in reproductive medicine and obstetrics. The booth attracted strong interest from doctors, embryologists, and healthcare professionals thanks to features such as:

Introduction of advanced genetic testing solutions: PGT-A/PGT-SR, PGT-M (100+ rare diseases), PGT Upgrade, PGT Next, reproductive hormone assessment tests, preconception genetic screening, high-tech NIPT, genetic tests related to male infertility, and more

Expert consultations from a knowledgeable and experienced team

Direct discussions on clinical applications to help doctors optimize testing indications


Beyond technical information, the Eurofins GENTIS booth also brought a lively atmosphere to the conference through mini-games and appreciation gifts for delegates. This was also an opportunity for GENTIS to connect and gather valuable feedback from clinicians to improve future services.

Commitment to advancing reproductive healthcare in Vietnam
Eurofins GENTIS continues to strive to bring cutting-edge genetic technologies to Vietnam, enhancing testing quality and improving the effectiveness of assisted reproduction. Our presence at the 20th HOSREM Conference reflects our ongoing commitment to supporting the development of the healthcare sector.
We believe that when applied appropriately, genetic testing solutions can help clinicians optimize infertility treatment protocols, improve embryo quality, increase IVF success rates, reduce pregnancy risks through early screening, and support clinical decision-making based on scientific evidence—ultimately contributing to better population health and community well-being.
The strong interest from delegates visiting the Eurofins GENTIS booth is an important motivation for us to continue researching, innovating, and expanding high-quality genetic services for the Vietnamese community.
The 20th Annual HOSREM Scientific Conference concluded with meaningful scientific highlights, open discussions, and valuable professional connections. Eurofins GENTIS extends our sincere thanks to the HOSREM Organizing Committee, chairpersons, speakers, and all delegates for contributing to the overall success of the event.
We believe that the knowledge shared during the conference, together with the genetic solutions presented at the Eurofins GENTIS booth, will provide practical support for clinicians nationwide in examination and treatment. This is the core value that GENTIS consistently pursues: accompanying medical professionals and elevating reproductive healthcare in Vietnam.
Eurofins GENTIS once again congratulates the HOSREM 20th Annual Scientific Conference on its outstanding success! We look forward to meeting you again at upcoming major scientific events across the country.

            [content_more] => 
            [meta_title] => Eurofins GENTIS congratulates the 20th annual HOSREM scientific conference on its great success
            [meta_description] => On November 23, 2025, the 20th Annual HOSREM scientific conference took place at the Equatorial Hotel in Ho Chi Minh City, attracting a large number of doctors and experts in reproductive endocrinology, assisted reproduction, and embryology from across th
            [meta_keyword] => GENTIS,HOSREM
            [thumbnail_alt] => 
            [post_id] => 1382
            [category_id] => 15
        )

    [3] => stdClass Object
        (
            [id] => 1380
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 583886482_1245783690902579_3797177799609396580_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-11-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-11-18 10:48:14
            [updated_time] => 2025-11-18 10:51:36
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 0
            [language_code] => en
            [slug] => Genetics-in-assisted-reproduction-breakthroughs-bringing-new-hope-to-infertile-couples
            [title] =>  Genetics in assisted reproduction – breakthroughs bringing new hope to infertile couples
            [description] => Over the years, infertility has become one of the major concerns of modern medicine. Statistics show that as many as 12.6% of couples worldwide face difficulties in conceiving. The causes may stem from the husband, the wife, both partners, or in some cases cannot be clearly identified. However, alongside advances in assisted reproductive technologies (ART), particularly the groundbreaking applications of genetics, the journey to parenthood for infertile couples is now more hopeful than ever.
            [content] => 
From fundamental techniques such as in vitro fertilization, medicine has continuously achieved remarkable progress. One of the most significant milestones is the application of genetics in assisted reproduction—allowing doctors not only to create embryos but also to select the healthiest ones, thereby increasing the chances of success.

According to Assoc. Prof. Dr. Trinh The Son – Director of the Military Clinical Embryology Institute, Vietnam Military Medical Academy – genetics now plays a pivotal role in the field of assisted reproduction. Through genetic and chromosomal analyses, doctors can identify the root causes of infertility at the deepest biological levels, detecting chromosomal abnormalities such as Klinefelter syndrome, Turner syndrome, or AZF microdeletions in men, as well as gene mutations that may lead to vas deferens obstruction or premature ovarian failure. More importantly, genetic information enables personalized treatment regimens tailored to each patient’s genetic characteristics.
One of the most prominent achievements in this field is preimplantation genetic testing (PGT). This technique allows doctors to select embryos with normal chromosomal makeup and eliminate those carrying abnormalities that may lead to miscarriage or genetic disorders. PGT includes several types such as PGT-A, PGT-M, and PGT-SR. PGT-A helps detect abnormalities in chromosome numbers, such as Down syndrome; PGT-M is used for couples carrying genetic diseases like Thalassemia or cystic fibrosis to ensure only embryos without the disease-causing gene are transferred; while PGT-SR helps detect structural chromosomal abnormalities such as translocations or inversions, proving particularly valuable in cases of recurrent miscarriage or unexplained infertility.
Beyond these, scientists are researching and applying non-invasive screening methods, notably niPGT – a technique analyzing cell-free DNA in embryo culture media, eliminating the need for embryo biopsy and improving embryo safety during development.
In addition, the emergence of advanced tests such as PGT NEXT, PGT UPGRADE, WES, and WGS is significantly improving success rates in assisted reproduction. PGT NEXT enables comprehensive chromosomal assessment of embryos, detecting aneuploidy, mono- and polyploidy, as well as structural abnormalities, while using SNP analysis to prevent sample mix-ups and accurately identify healthy diploid embryos. PGT UPGRADE goes a step further by detecting embryos carrying balanced translocations inherited from parents—a common cause of recurrent miscarriage—allowing doctors to select embryos without such abnormalities and improving the chances of a healthy pregnancy for couples with chromosomal translocations.

Meanwhile, WES (whole exome sequencing) and WGS (whole genome sequencing) open the door to identifying rare, complex, or previously unknown mutations related to infertility. WES examines more than 22,000 coding genes—where most disease-causing variants are concentrated—while WGS provides the most comprehensive genomic overview, helping doctors uncover deep-seated causes in difficult cases, thereby personalizing treatment plans and optimizing patient success rates.

Artificial intelligence and big data analytics are also becoming powerful tools for selecting embryos with the highest developmental potential. AI systems can analyze thousands of data points on embryo morphology and development speed to suggest the healthiest embryo, significantly increasing success rates for infertile couples.
Genetics not only enhances the effectiveness of infertility treatment but also aims toward selecting healthy embryos, ensuring precise treatment, and preventing genetic diseases. Assoc. Prof. Dr. Trinh The Son emphasizes that it is essential to approach these technologies with humanity and responsibility so that science truly serves human happiness.
On the journey toward parenthood, each advancement in genetic medicine is a beacon of hope—illuminating the dreams of millions of infertile families and bringing them closer to the “miracle of life.”

            [content_more] => 
            [meta_title] =>  Genetics in assisted reproduction – breakthroughs bringing new hope to infertile couples
            [meta_description] => Over the years, infertility has become one of the major concerns of modern medicine. Statistics show that as many as 12.6% of couples worldwide face difficulties in conceiving. 
            [meta_keyword] => GENTIS,PGT,WES,WGS
            [thumbnail_alt] => 
            [post_id] => 1380
            [category_id] => 15
        )

    [4] => stdClass Object
        (
            [id] => 1379
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => hoi-nghi-khoa-hoc-hosrem-lan-thu-20.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-11-17
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-11-17 14:25:06
            [updated_time] => 2025-11-21 10:09:07
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-accompanies-the-20th-annual-HOSREM-scientific-conference
            [title] => Eurofins GENTIS accompanies the 20th annual HOSREM scientific conference
            [description] => On November 23, 2025, the 20th Annual HOSREM Scientific Conference will officially take place at the Equatorial Hotel in Ho Chi Minh City, marking an important milestone for one of the most prestigious scientific forums in the fields of obstetrics–gynecology and reproductive health in Vietnam. This year, Eurofins GENTIS is honored to join the conference as the main sponsor, offering a wide range of professional activities and meaningful interactions for attending delegates.
            [content] => 
HOSREM – 20 Years of Knowledge Building and Expert Connection
The HOSREM Annual Scientific Conference is a reputable forum in obstetrics–gynecology and reproductive health, where the latest knowledge and advances are shared by leading experts. Over the past 20 years, HOSREM has grown into a major scientific event, gathering numerous delegates from hospitals and medical centers across the country.
Beyond being a venue for updating specialized knowledge, HOSREM serves as a bridge connecting scientific research, clinical experience, and practical applications in reproductive healthcare. Throughout its 20 editions, HOSREM has consistently remained a trusted platform for academic exchange and for sharing the latest medical advancements. It also promotes collaboration among hospitals, medical centers, and research institutes both domestically and internationally. In addition, HOSREM inspires innovation and encourages the integration of technology into reproductive healthcare in Vietnam.
This year's conference continues to bring together leading experts from major hospitals, reproductive centers, laboratories, and healthcare organizations nationwide, offering a comprehensive and in-depth picture of the current landscape in obstetrics and gynecology.

2025 Conference Themes: Addressing Key Issues in Clinical Practice
The 20th HOSREM Conference will focus on practical and highly relevant topics in obstetrics, gynecology, and assisted reproduction. This year’s program highlights common and critical issues in clinical practice, featuring engaging presentations by seasoned experts and physicians, promising valuable updates and insights for all attendees.
A major highlight of this year’s event is the participation of top Vietnamese specialists in IVF, fetal medicine, medical genetics, and reproductive healthcare. They will present up-to-date research findings, unique clinical cases, and emerging trends that help improve treatment outcomes.
In addition to scientific presentations, open discussion sessions will offer delegates the opportunity to exchange experiences, share clinical challenges, and explore feasible solutions for patients in today’s context.
Eurofins GENTIS – Partnering with HOSREM for a future of comprehensive reproductive health
With the mission “Enhancing the Physical and Intellectual Well-being of Vietnamese People,” Eurofins GENTIS joins HOSREM 2025 as a main sponsor, bringing advanced genetic solutions that support obstetrics and assisted reproduction.
Over the years, Eurofins GENTIS has continuously improved testing quality by adopting cutting-edge technologies from Eurofins Scientific—one of the world’s largest laboratory groups. GENTIS’s specialized genetic tests play a significant role in:

Optimizing IVF cycles through embryo genetic assessments (PGT-A/PGT-SR, PGT-M for 100+ rare diseases, PGT-Upgrade, PGT-Next).

Preconception carrier screening for couples to reduce the risk of passing on genetic disorders.

Non-invasive prenatal testing (NIPT) for early detection of chromosomal abnormalities in the first trimester.

Testing to evaluate treatment responsiveness in infertility, helping physicians develop tailored protocols.


Eurofins GENTIS firmly believes that integrating genetic testing into clinical practice not only improves treatment efficacy but also gives families the chance to welcome healthy babies while reducing risks and healthcare burdens.
Eurofins GENTIS Booth – A Highlight of the Conference
At this year’s conference, the Eurofins GENTIS booth is designed to provide a friendly and modern space where delegates can:

Receive direct consultation from experts on genetic testing for obstetrics and assisted reproduction.

Access the latest updates on the company’s genetic testing solutions.

Participate in a mini-game program for visitors—an engaging activity aimed at creating a lively atmosphere and expressing our appreciation to the physicians and experts who have supported GENTIS over the years.


We believe that the development of obstetrics, gynecology, and assisted reproduction cannot be separated from the advancement of genetic testing technologies. Our continued partnership with HOSREM reflects GENTIS’s commitment to contributing to shared goals:

Improving treatment quality for infertility patients.

Helping reduce birth defects through genetic screening and diagnosis.

Supporting physicians in staying updated on new research and technologies.


As the demand for reproductive healthcare grows, the integration of genomics into clinical practice becomes essential to ensure optimal treatment outcomes and improve population health.
The 20th Annual HOSREM Scientific Conference promises to be a knowledge-rich, inspiring event that fosters meaningful collaborations among medical institutions, hospitals, reproductive centers, and laboratories nationwide.
Eurofins GENTIS warmly invites all delegates to visit our booth for professional exchange, information sharing, and hands-on experience with the most advanced genetic solutions available today.
We look forward to welcoming you at HOSREM 2025—where knowledge converges, connections flourish, and innovation begins!
            [content_more] => 
            [meta_title] => Eurofins GENTIS accompanies the 20th annual HOSREM scientific conference
            [meta_description] => On November 23, 2025, the 20th Annual HOSREM Scientific Conference will officially take place at the Equatorial Hotel in Ho Chi Minh City, marking an important milestone for one of the most prestigious scientific forums in the fields of obstetrics–gynecol
            [meta_keyword] => GENTIS,HOSREM
            [thumbnail_alt] => 
            [post_id] => 1379
            [category_id] => 15
        )

    [5] => stdClass Object
        (
            [id] => 1374
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 565146852_1222653929882222_4756649354324039800_n_(1).jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-10-28
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-10-28 08:27:20
            [updated_time] => 2025-10-28 10:10:27
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => GENTIS-honored-to-welcome-CAP-expert-delegation-at-headquarters-Hanoi
            [title] => GENTIS honored to welcome CAP expert delegation at headquarters - Hanoi
            [description] => On October 17, 2025, GENTIS had the honor of welcoming a delegation of senior experts from the College of American Pathologists (CAP) – the world’s leading organization in clinical laboratory accreditation – to visit and work at its headquarters in Hanoi.
            [content] => 
This visit marks a significant milestone, underscoring the strong and enduring partnership between GENTIS and CAP in maintaining and advancing international quality standards for laboratory testing in Vietnam. It also provided an opportunity for both parties to engage in in-depth discussions on sustainable development strategies and future cooperation directions, contributing to the growth of Vietnam’s genetic testing industry to regional and global levels.
The CAP delegation included senior leaders with extensive experience in laboratory science and international market development. Among them were Ms. Xiaocong (Angra) Wang, Regional Leader for Southeast Asia, South Asia, and Oceania; Ms. Elizabeth Tudor, Senior Leader in Global Support and Development; Mr. Sean Harrington, Director of International Market Development; and Mr. Brian Nowlin, Vice President of International Market Development at CAP. The participation of these distinguished experts brought valuable insights, strategic perspectives, and collaboration opportunities for advancing testing standards in Vietnam.

During the working session, the CAP delegation and GENTIS leadership, along with its technical team, exchanged knowledge and international experience in laboratory quality management. They also shared strategic perspectives on developing efficient operational models aimed at transparency and standardization in accordance with CAP standards. The delegation directly visited the PGT and NIPT laboratories, both of which achieved CAP accreditation in June 2025—an important milestone affirming GENTIS’s commitment to quality and credibility.
The College of American Pathologists (CAP) is one of the most prestigious organizations in the world for medical laboratory accreditation and inspection, recognized in over 100 countries. Achieving CAP accreditation means that a laboratory meets the most stringent requirements for operational processes, personnel competence, and test result accuracy. Therefore, GENTIS’s attainment of this certification is not only a source of pride but also clear evidence of its continuous efforts to ensure world-class service quality.
During the visit, the CAP delegation highly commended GENTIS for its investment in modern equipment, strict adherence to quality management procedures, and development of a highly qualified workforce. GENTIS’s achievements in implementing CAP standards reaffirm its professional expertise and pioneering position in the field of genetic testing.
GENTIS is committed to providing laboratory testing services that are accurate, safe, and transparent. Its continuous efforts to maintain, strengthen, and expand international standards such as CAP demonstrate GENTIS’s strong commitment to quality and sustainable development.

The visit and working session with the CAP delegation not only recognized GENTIS’s accomplishments but also opened new avenues for potential collaboration in the future. With a solid foundation of expertise, technology, and human resources, GENTIS continues to affirm its leading position in genetic testing in Vietnam and contributes to the advancement of modern medicine in the region.
            [content_more] => 
            [meta_title] => GENTIS honored to welcome CAP expert delegation at headquarters - Hanoi
            [meta_description] => On October 17, 2025, GENTIS had the honor of welcoming a delegation of senior experts from the College of American Pathologists (CAP) – the world’s leading organization in clinical laboratory accreditation – to visit and work at its headquarters in Hanoi.
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1374
            [category_id] => 15
        )

    [6] => stdClass Object
        (
            [id] => 1372
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 565102005_1221798849967730_2421886531515618477_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-10-22
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-10-22 13:36:34
            [updated_time] => 2025-10-28 10:24:37
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Screening-and-dianostic-test-panel-for-male-infertility-Experience-from-Eurofins-GENTIS-labolatory
            [title] => Screening and diagnostic test panel for male infertility: Experience from Eurofins - GENTIS laboratory
            [description] => Male infertility is a sensitive topic that is sometimes overlooked during infertility consultations. However, in reality, it accounts for nearly 50% of infertility cases among couples. While women are often evaluated early, many men are not diagnosed in time, leading to delayed treatment or even the selection of inappropriate assisted reproductive methods.
            [content] => 
In response to this reality, Eurofins - GENTIS has developed a comprehensive testing panel aimed at accurately screening and diagnosing the causes of male infertility. This panel not only helps doctors identify the root causes but also allows for individualized treatment plans, optimizing the chances of conception for couples.
Medical research shows that male infertility can arise from multiple causes: about 70% result from testicular defects, 15% are related to endocrine disorders, 5% involve sperm motility issues, and 10% remain unexplained. Notably, genetic factors are implicated in approximately 15% of male infertility cases. These factors may include chromosomal abnormalities, gene mutations, or epigenetic disorders, which cannot be detected using standard tests. Early detection of these genetic factors is crucial not only for accurately assessing spermatogenic potential but also for preventing the transmission of genetic disorders to future generations through controlled assisted reproductive methods such as IVF combined with PGT-M.
Dr. Vu Thu Huong (GENTIS) presented on genetic causes of male infertility at the VSSM 2025 Conference
Therefore, the process of evaluating male infertility follows a standardized protocol in line with recommendations from the European Association of Urology (EAU, 2025), the American Society for Reproductive Medicine (ASRM), and expert consensus. First, all men suspected of infertility undergo a thorough medical history review and clinical examination to evaluate relevant parameters.
The goal of the initial assessment is to identify cases that can be treated or couples with male-factor infertility who may benefit from assisted reproductive interventions. Depending on the results, further investigations may be conducted, such as testicular ultrasound to detect conditions like hydrocele or varicocele—common but treatable causes if detected early. Physicians may also order endocrine and extended tests, particularly genetic tests, to identify the underlying cause of infertility.
Semen analysis is the first and fundamental test for evaluating sperm quality. It measures sperm concentration, motility, and morphology. If abnormalities are found, the test is typically repeated after 2–3 weeks to rule out temporary factors such as stress, acute illness, or environmental influences. Additionally, endocrine evaluation through FSH, LH, and testosterone levels helps differentiate primary versus secondary hypogonadism, especially in cases with very low sperm counts (<5 million/mL).
Karyotype testing is a key genetic test performed at Eurofins - GENTIS. It is indicated for patients with azoospermia or severe oligozoospermia (sperm count <5 million/mL) to detect numerical or structural chromosomal abnormalities, such as Klinefelter syndrome (47,XXY) or chromosomal deletions and translocations. This allows physicians to provide prognosis regarding spermatogenic potential and guide appropriate treatment.
Dr. Huong shared various screening and diagnostic tests for male infertility
Another common genetic cause of male infertility is microdeletions in the AZF region of the Y chromosome, which is the second most frequent genetic factor after chromosomal abnormalities. AZFa, AZFb, and AZFc regions contain genes essential for spermatogenesis, and deletions in these areas can directly cause infertility. Testing is indicated for azoospermic men or those with sperm counts below 5 million/mL, and is mandatory for counts below 1 million/mL. Identifying deletions in AZFa or AZFb is crucial because affected patients typically lack spermatogenic potential, preventing unnecessary interventions, while AZFc deletions may still allow for sperm retrieval and assisted reproduction. This test also plays a role in genetic counseling, as Y chromosome deletions in the father can be inherited by sons via ICSI.
Another cause of obstructive male infertility is congenital absence of the vas deferens (CBAVD), commonly associated with CFTR gene mutations causing cystic fibrosis. Men with low semen volume (<1 mL), acidic semen (pH <7.0), and absent sperm, along with relevant clinical history, are tested for CFTR mutations. At GENTIS, this test uses PCR combined with Sanger sequencing to detect 22 common CFTR mutations, including variants like Val470Met and Arg117His, as well as IVS8 polymorphisms. Results allow physicians to identify CBAVD-related infertility and plan treatments such as vas deferens reconstruction, testicular sperm extraction, or IVF/ICSI, while providing genetic counseling to prevent cystic fibrosis in offspring.
Beyond basic genetic tests, sperm DNA fragmentation (SDF) testing is an important tool in diagnosing male infertility, particularly in unexplained infertility, recurrent miscarriage, or repeated IVF/ICSI failure. At GENTIS, SDF is performed using the SCSA method, which employs specialized fluorescent dyes and flow cytometry to assess sperm DNA damage. Based on SDF results, physicians can recommend lifestyle modifications (e.g., quitting smoking, weight loss, reducing environmental toxin exposure, antioxidant supplementation) or interventions such as varicocele repair or advanced sperm selection techniques like PICSI or MACS to improve treatment outcomes.
Dr. Huong discussed the benefits of genetic testing in male infertility screening and diagnosis
At the 2025 National VSSM Scientific Conference, MSc. Dr. Vu Thu Huong (R&D Specialist at GENTIS) noted that in 30–40% of cases, even after all standard tests, the cause of infertility remains unknown. Next-generation sequencing (NGS) offers a breakthrough by analyzing large panels of genes related to spermatogenesis, identifying rare or novel mutations. Targeted gene panels or whole exome sequencing (WES) can determine molecular-level causes. However, incidental findings or variants of uncertain significance (VUS) may complicate counseling and treatment decisions. GENTIS has a team of genetic experts capable of multidisciplinary consultation and international database review to provide personalized guidance.
Dr. Huong emphasized that not every patient requires genetic testing; it should be performed only with clear clinical indications. Selecting the appropriate test prevents unnecessary interventions, accurately identifies the cause of infertility, enables individualized treatment, informs the choice of assisted reproduction methods, guides PGT-M if needed, and most importantly, reduces risk for future generations.
With over 15 years of experience in genetic testing, Eurofins - GENTIS is a pioneer in Vietnam in applying genetic diagnostics to male infertility. Beyond being a laboratory, GENTIS collaborates with doctors, fertility centers, and patients to make precise, individualized treatment decisions, ultimately helping couples achieve their dream of parenthood safely and sustainably.
            [content_more] => 
            [meta_title] => Screening and diagnostic test panel for male infertility: Experience from Eurofins - GENTIS laborato
            [meta_description] => Male infertility is a sensitive topic that is sometimes overlooked during infertility consultations.
            [meta_keyword] => GENTIS,PGT
            [thumbnail_alt] => 
            [post_id] => 1372
            [category_id] => 15
        )

    [7] => stdClass Object
        (
            [id] => 1370
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => rabbit_media-2484.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-10-22
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-10-22 09:50:11
            [updated_time] => 2025-10-23 09:37:43
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => GENTIS-parners-with-HSMFM-2025-joining-hands-to-improve-the-quality-of-maternal-and-fetal-healthcare-in-Vietnam
            [title] => GENTIS partners with HSMFM 2025: Joining hands to improve the quality of maternal and fetal healthcare in Vietnam
            [description] => The Ho Chi Minh City Maternal and Fetal Medicine Conference 2025 (HSMFM 2025) successfully concluded after two vibrant days from October 18 to 19, 2025, held at the Grand Saigon Hotel and Sheraton Saigon. With nearly 700 delegates and over 30 domestic and international speakers and chairpersons participating, the event once again affirmed its leading position in obstetrics and gynecology, fetal medicine, and genetics in Vietnam. Under the shared theme, "For the Health of Vietnamese Mothers and Fetuses," the conference was not only a platform for sharing the latest knowledge but also a bridge connecting research, application, and clinical practice.
            [content] => 

As a co-sponsor of this conference, GENTIS’s participation further demonstrates its strong commitment to promoting the application of genetic medicine in reproductive healthcare. Beyond providing advanced technological solutions, GENTIS contributed to the professional program with up-to-date content aimed at practical value for doctors and specialists.
One of the key highlights introduced by GENTIS at the conference was two modern genetic testing solutions widely applied in Vietnam, recently certified by the College of American Pathologists (CAP)—one of the top international standards for medical laboratories. Among them, the NIPT test (Non-Invasive Prenatal Testing) is increasingly becoming the standard in modern pregnancy management. With the ability to detect genetic abnormalities as early as the 9th week of pregnancy using only maternal blood samples, NIPT minimizes risks associated with invasive procedures like amniocentesis, while providing accurate information for doctors and expectant mothers to make informed medical decisions. Discussions at the conference clearly emphasized the importance of broad NIPT implementation, especially given the still-high rates of late detection of congenital abnormalities in many localities.

Additionally, GENTIS highlighted the role of PGT (Preimplantation Genetic Testing) in the field of assisted reproduction. Embryo screening before transfer—not only improving IVF success rates but also reducing the risk of passing genetic disorders to the next generation. With the rising rate of infertility and increasing demand for healthy childbirth, applying PGT has become an essential part of IVF protocols at many leading fertility centers. GENTIS currently offers PGT-A, PGT-M, and PGT-SR tests, expanding screening capabilities from chromosomal abnormalities to complex single-gene disorders.

Notably, at this conference, GENTIS proudly sponsored a scientific report titled “Gene Therapy in Fetuses: From Potential to Clinical Practice,” presented by Dr. Nguyen Van Thong—Head of Medical Genetics Department, Hung Vuong Hospital. The report attracted significant attention from the professional community as it discussed the emerging and promising field of gene therapy in fetal medicine. Developing gene therapies administered before birth, if systematically advanced, could fundamentally change the approach to treating congenital genetic diseases in Vietnam in the near future. This aligns with GENTIS’s long-term vision—not only providing genetic testing services but also accompanying the medical community in research, application, and technology transfer of advanced medical innovations.
HSMFM 2025 also served as a forum for experts to deeply discuss the standardization of fetal screening, diagnosis, and intervention processes, sharing experiences in managing high-risk pregnancies, and enhancing genetic counseling capacity. Case discussion sessions provided fresh insights, highlighting the urgent need for continuous knowledge updates and applying scientific technology to improve treatment quality.
By partnering with HSMFM 2025, GENTIS not only demonstrated its role as a reputable provider of genetic medicine services but also as a crucial link in Vietnam’s healthcare innovation ecosystem. This event marked another important milestone in GENTIS’s ongoing journey to contribute to building a preventive, precise, and personalized healthcare system, aiming to improve quality of life from the earliest stage—right from the womb.
            [content_more] => 
            [meta_title] => GENTIS partners with HSMFM 2025: Joining hands to improve the quality of maternal and fetal healthca
            [meta_description] => The Ho Chi Minh City Maternal and Fetal Medicine Conference 2025 (HSMFM 2025) successfully concluded after two vibrant days from October 18 to 19, 2025, held at the Grand Saigon Hotel and Sheraton Saigon.
            [meta_keyword] => GENTIS,HSMFM 2025
            [thumbnail_alt] => 
            [post_id] => 1370
            [category_id] => 15
        )

)